Lila Biologics was founded as a spin-out from David Baker's lab, with a focus on radioligand therapies, involving Anindya Roy.
1 report, 1 independent
Updated Sep 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Lila Biologics was founded as a spin-out from David Baker's lab, with a focus on radioligand therapies, involving Anindya Roy.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Eli Lilly and Company
American pharmaceutical company
- Global market sentiment is being influenced by geopolitical conflict in the Middle East, impacting the competitive landscape of diabetes and obesity drug companies like Novo Nordisk and Eli Lilly.
- FDA approved Rasonque for pancreatic cancer, while Revolution Medicines evaluates therapy with Merck's Keytruda and compares its market cap to Eli Lilly.
-
David Baker
researcher (ORCID 0000-0001-8651-865X)
Nothing else this week.
Related events
Coverage
Newest first; wire copies grouped- GlobeNewswireLila Biologics Announces Collaboration with Lilly For Radioligand Therapy Discovery and Development Biotech Company Introduces Protein Therapeutics Platforms to Combat Cancer and Non-Oncology Disease